Clinical Trials Browser

Phase 1/2 × OTHER_GOV × camrelizumab × Clear all

NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Phase 1/2 Unknown

Triple Negative Breast Neoplasms